Have a personal or library account? Click to login
Current Operating Procedure (COP) for Bleomycin ElectroScleroTherapy (BEST) of low-flow vascular malformations Cover

Current Operating Procedure (COP) for Bleomycin ElectroScleroTherapy (BEST) of low-flow vascular malformations

Open Access
|Nov 2024

Figures & Tables

FIGURE 1.

After Bleomycin ElectroScleroTherapy (BEST) flagellate dermatitis can occur on the sites of skin. (A) Scratching can cause permanent hyperpigmentation due to bleomycin. (B) Marks of the electrode insertion are visible at the site of the treatment.
After Bleomycin ElectroScleroTherapy (BEST) flagellate dermatitis can occur on the sites of skin. (A) Scratching can cause permanent hyperpigmentation due to bleomycin. (B) Marks of the electrode insertion are visible at the site of the treatment.

FIGURE 2.

Procedure of Bleomycin ElectroScleroTherapy (BEST) in the treatment of low-flow vascular malformation on the lip. (A) Patient pre-treatment. (B) After the injection of bleomycin solution, the (C) electric pulses were applied on several areas with the finger electrode, avoiding overlap of the electric field. Procedure was completed in 10 minutes. The treated malformation was compressed (D) for several minutes to stop bleeding. Due to the vascular effects of BEST, the bleeding stopped spontaneously.
Procedure of Bleomycin ElectroScleroTherapy (BEST) in the treatment of low-flow vascular malformation on the lip. (A) Patient pre-treatment. (B) After the injection of bleomycin solution, the (C) electric pulses were applied on several areas with the finger electrode, avoiding overlap of the electric field. Procedure was completed in 10 minutes. The treated malformation was compressed (D) for several minutes to stop bleeding. Due to the vascular effects of BEST, the bleeding stopped spontaneously.

FIGURE 3.

Example of Bleomycin ElectroScleroTherapy (BEST) treatment effectiveness on low-flow vascular malformation. After treatment, the treated area is oedematous, with a scab over the treated area after 3 weeks. The scab falls off in about 6 weeks with already visible treatment effectiveness. After 3 months, an excellent effect is visible after one treatment only.
Example of Bleomycin ElectroScleroTherapy (BEST) treatment effectiveness on low-flow vascular malformation. After treatment, the treated area is oedematous, with a scab over the treated area after 3 weeks. The scab falls off in about 6 weeks with already visible treatment effectiveness. After 3 months, an excellent effect is visible after one treatment only.

FIGURE 4.

Microcystic lymphatic malformation before Bleomycin ElectroScleroTherapy (BEST) (A) and one year after (B). A significant reduction of the malformation is observed.
Microcystic lymphatic malformation before Bleomycin ElectroScleroTherapy (BEST) (A) and one year after (B). A significant reduction of the malformation is observed.

Recommended preparation and dosing of intralesional injection (neat or foamed) of bleomycin for Bleomycin ElectroScleroTherapy (BEST)

ConcentrationPreparation for injectionMaximal dose per sessionCumulative dose in all sessions
Bleomycin and contrast1 000 IU/ml in NaCl solution1 part of solution in 3 parts of Contrast Medium (250 IU/ml)10 000 IU in adults100 000 IU in adults
200 IU/kg in children1 300 IU/kg in children-divided by number of sessions
Divide the total dose into anticipated number of sessions
The interval between sessions should be at least 8 weeks
Foamed bleomycin1 000 IU/ml in NaCl solution1 ml albumin; 1 ml plain 1% lidocaine; 8 000 IU bleomycin; contrast agent may be added; orthogonal 3 way tap connection; 5 ml air- or according to local practiceAs aboveAs above
DOI: https://doi.org/10.2478/raon-2024-0061 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 469 - 479
Submitted on: Sep 23, 2024
Accepted on: Oct 17, 2024
Published on: Nov 28, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Tobian Muir, Walter A Wohlgemuth, Maja Cemazar, Giulia Bertino, Ales Groselj, Lakshmi A Ratnam, Ian McCafferty, Moritz Wildgruber, Bernhard Gebauer, Francesca de Terlizzi, Alessandro Zanasi, Gregor Sersa, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.